Caputo Louis, Richa Yasmina, Balcer Kaja, Beugniez César, Vermersch Mathilde, Bourry Julien, Cailliau Emeline, Truant Stephanie, El Amrani Mehdi
Department of Digestive Surgery and Transplantation, Lille University Hospital, Lille, France.
School of Medicine, University College Cork, Cork, Ireland.
J Gastrointest Oncol. 2025 Jun 30;16(3):1305-1313. doi: 10.21037/jgo-24-700. Epub 2025 Jun 24.
The relation between sarcopenia and hepatic steatosis is well established. However, to our knowledge, no study has explored this relationship in patients undergoing pancreatic surgery. The aim of this study is to determine whether pre-operative sarcopenia has an impact on hepatic density attenuation after pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC).
In this retrospective cohort study, all patients who underwent PD in Lille University Hospital between 2011 and 2020 were included. Pre-operative sarcopenia was assessed using Skeletal Muscle Index (SMI) measurements, cut-offs for the sarcopenic group were 38.9 cm/m for women and 55.4 cm/m for men. Hepatic steatosis was defined as a mean hepatic density <40 Hounsfield units (HU). We measured liver density on pre- and post-operative CT scans at 1, 6 months and after 6 months. Liver density attenuation was compared between sarcopenic and non-sarcopenic groups.
One hundred and nine patients were included. Sixty-six patients (61%) were diagnosed with pre-operative sarcopenia and 39 (36%) presented post-operative hepatic steatosis within the first 6 months. No significant difference was shown between the two groups in terms of liver density attenuation before and after surgery (P=0.97). In the multivariate analysis, lower age [odds ratio (OR): 0.57, 95% confidence interval (CI): 0.36-0.89, P=0.01] and higher body mass index (BMI) (OR: 1.61, 95% CI: 1.02-2.57, P=0.04) were risk factors for hepatic steatosis after PD for PDAC. Pre-operative sarcopenia and post-operative hepatic steatosis within the first 6 months had no impact on 3 years survival.
Pre-operative sarcopenia had no significant impact on liver density attenuation before and after surgery. Lower age and higher BMI are associated with post-PD hepatic steatosis in patients with PDAC. Prospective studies should be considered to clarify these results.
肌肉减少症与肝脂肪变性之间的关系已得到充分证实。然而,据我们所知,尚无研究探讨胰腺手术患者中的这种关系。本研究的目的是确定术前肌肉减少症是否对胰腺导管腺癌(PDAC)行胰十二指肠切除术(PD)后的肝脏密度衰减有影响。
在这项回顾性队列研究中,纳入了2011年至2020年在里尔大学医院接受PD的所有患者。使用骨骼肌指数(SMI)测量评估术前肌肉减少症,肌肉减少症组的临界值女性为38.9 cm/m,男性为55.4 cm/m。肝脂肪变性定义为平均肝脏密度<40亨氏单位(HU)。我们在术前、术后1个月、6个月及6个月后进行的CT扫描上测量肝脏密度。比较肌肉减少症组和非肌肉减少症组的肝脏密度衰减情况。
共纳入109例患者。66例患者(61%)被诊断为术前肌肉减少症,39例(36%)在术后前6个月出现术后肝脂肪变性。两组在手术前后的肝脏密度衰减方面无显著差异(P=0.97)。在多变量分析中,年龄较低[比值比(OR):0.57,95%置信区间(CI):0.36 - 0.89,P=0.01]和体重指数(BMI)较高(OR:1.61,95%CI:1.02 - 2.57,P=0.04)是PDAC行PD术后肝脂肪变性的危险因素。术前肌肉减少症和术后前6个月内的术后肝脂肪变性对3年生存率无影响。
术前肌肉减少症对手术前后的肝脏密度衰减无显著影响。年龄较低和BMI较高与PDAC患者PD术后的肝脂肪变性有关。应考虑进行前瞻性研究以阐明这些结果。